Ipsen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.04.12	Ipsen’s Partner, Inspiration Biopharmaceuticals, Announces US Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for the Treatment of Hemophilia B (Businesswire)
06.04.12	IPSEN : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.04.12	The 20th Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences Series: "Programmed Cells: from Basic Neuroscience to Therapy” (Businesswire)
02.04.12	The Ipsen Group publishes its 2011 Registration document (Businesswire)
05.03.12	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
29.02.12	Ipsen’s 2011 Results and 2012 Objectives (Businesswire)
24.02.12	Active Biotech and Ipsen Report Tasquinimod (TASQ) Phase II Long Term Safety Data at the 27th European Association of Urology (EAU) Congress (Businesswire)
07.02.12	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
02.02.12	Ipsen’s fourth quarter and full year 2011 sales and other significant developments (Businesswire)
27.01.12	Ipsen Acknowledges Tanakan® Delisting in France (Businesswire)
24.01.12	Santhera erhält Fipamezole-Rechte von Ipsen zurück; Fokus bleibt auf Catena (AF) (AWP)
24.01.12	Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement (Businesswire)
12.01.12	Half-Year IPSEN Liquidity Contract Statement Entered into With NATIXIS (Businesswire)
05.01.12	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
05.01.12	Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson's disease target (Businesswire)
04.01.12	Ipsen announces its corporate agenda for 2012 (Businesswire)
06.12.11	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) (Businesswire)
06.12.11	U.S. Bancorp Fund Services, LLC Launches Exchange Traded Funds Service, ETF-Fusion™ (Businesswire)
06.12.11	PPG Announces Global Initiative to Leverage Titanium Dioxide Expertise (Businesswire)
02.12.11	The 20th Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen is Awarded to Prof. Patricia K. Kuhl (University of Washington, Seattle, USA) (Businesswire)
28.11.11	Ipsen’s partner Inspiration Biopharmaceuticals announces the initiation of the second phase III pivotal clinical study of OBI-1 in congenital hemophilia A with inhibitors (Businesswire)
07.11.11	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) (Businesswire)
03.05.11	Ipsen’s first quarter 2011 sales (Businesswire)
03.05.11	Ipsen’s first quarter 2011 sales (Businesswire)
02.03.11	Ipsen’s 2010 results and 2011 sales objectives (Businesswire)
31.08.10	Ipsen’s Half-year 2010 Results (Businesswire)
29.04.10	Ipsen’s Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint in a Key Phase III Clinical Trial (Businesswire)
27.04.10	Ipsen and Invida Enter into a Partnership for the Commercialization of Ipsen’s Specialty Care Drugs in South-East Asia (Businesswire)
30.03.10	Dicerna Pharmaceuticals and Ipsen Enter into an Exclusive Research Collaboration for the Development of New Therapeutic Agents in Endocrinology and Oncology (Businesswire)
01.03.10	Ipsen’s 2009 Results and Objectives (Businesswire)
08.01.10	Half-Year Statement of Ipsen’s Liquidity Contract (Businesswire)
13.11.09	Ipsen’s Decapeptyl® 6-Month Formulation Receives Marketing Authorization in France for the Treatment of Locally Advanced or Metastatic Prostate Cancer (Businesswire)
29.10.09	Ipsen’s First Nine Months of 2009 Sales and Update of Group Financial Objectives (Businesswire)
29.10.09	Ipsen’s Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint in the First Phase III Clinical Trial (Businesswire)
20.10.09	Ipsen Grants Menarini Exclusive European Licence Rights to Adenuric® (Febuxostat), Its Novel Treatment for Chronic Hyperuricaemia in Gout (Businesswire)
08.10.09	Ipsen and Spirogen Redesign Their Collaboration for the Development of SJG-136 (Now SG2000) (Businesswire)
15.09.09	Ipsen: Encouraging Preliminary New Data Available for the Treatment of Short Stature Children with Low IGF-1 Levels (Businesswire)
28.08.09	CORRECTING AND REPLACING: Ipsen’s Half Year 2009 Results (Businesswire)
28.08.09	Ipsen’s Half Year 2009 Results (Businesswire)
26.06.09	Ipsen: AZZALURE(R) Approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines (Businesswire)
30.04.09	Ipsen and Medicis: FDA Approves DysportTM for Therapeutic and Aesthetic Uses (Businesswire)
12.03.09	Ipsen: AZZALURE® Approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines (Businesswire)
02.03.09	Ipsen’s Full Year 2008 Results (Businesswire)
19.01.09	Ipsen: "Creating the Future: New Challenges in Biology and Medicine” (Businesswire)
08.01.09	Ipsen Provides Update on R&D Pipeline and Business Opportunities at Its Investor Day (Businesswire)
29.12.08	FDA Issues Complete Response Letter to Ipsen for Dysport® Biologics License Application (Businesswire)
12.12.08	Ipsen: AFEP / MEDEF Recommendations on Compensation of Executive Directors (Businesswire)
30.09.08	Ipsen: FDA's First-Cycle Review of Dysport(R) to Be Completed by Year-End (Businesswire)
29.08.08	Ipsen's Half Year 2008 Results and Update on Standalone Financial Objectives for the Full Year 2008 (Businesswire)
31.07.08	Ipsen's First Half 2008 Sales, Outlook for the Full Year 2008 and R&D Pipeline Update (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.59	0.72 %	K V
Lonza Grp	534.00	0.56 %	K V
Part Grp Hldg	1’257.00	0.48 %	K V
Swisscom	506.00	0.40 %	K V
Holcim	88.76	0.38 %	K V
CieFinRichemont	121.90	-0.37 %	K V
UBS Group	27.56	-0.72 %	K V
ABB	49.13	-0.83 %	K V
Sika	225.80	-1.22 %	K V
Logitech Intl	70.40	-2.20 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ipsen

Aktien Top/Flop

Meistgelesene Nachrichten